Combination therapy with 5-fluorouracil (5-FU; NSC-19893) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) for disseminated gastrointestinal carcinoma.
D000328:Adult; D000368:Aged; D000741:Anemia, Aplastic / Q000139:chemically induced; D001772:Blood Cell Count; D002277:Carcinoma / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy; D048909:Diabetes Complications; D001068:Feeding and Eating Disorders / Q000150:complications; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use*; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced; D005770:Gastrointestinal Neoplasms / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009607:Nitrosourea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D013274:Stomach Neoplasms / Q000188:drug therapy; D013921:Thrombocytopenia / Q000139:chemically induced
D009607:Nitrosourea Compounds; D005472:Fluorouracil